FDA Advisory Panel Votes 10-3 to Support Replimune's RP1, Sending REPL Stock Soaring 127% After Hours
According to an FDA advisory panel on Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that clinical study results for Replimune's RP1 therapy were reliable and clinically meaningful for patients with advanced melanoma who had progressed on prior anti-PD-1 therapy.
GateNews·07-31 00:13
